Variations in Practice Among Cirrhotic Patients With Portal Vein Thrombosis and Esophageal Varices: A North American Survey Study.

Item request has been placed! ×
Item request cannot be made. ×
loading   Processing Request
Read More Add to Saved list
  • Additional Information
    • Source:
      Publisher: Wolters Kluwer Health Country of Publication: United States NLM ID: 0421030 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1572-0241 (Electronic) Linking ISSN: 00029270 NLM ISO Abbreviation: Am J Gastroenterol Subsets: MEDLINE
    • Publication Information:
      Publication: <2019-> : [Philadelphia, PA] : Wolters Kluwer Health
      Original Publication: New York, Elsevier Science, -2003.
    • Subject Terms:
      Esophageal and Gastric Varices*/etiology ; Esophageal and Gastric Varices*/therapy ; Liver Diseases*/pathology ; Varicose Veins* ; Venous Thrombosis*/etiology; Humans ; Portal Vein ; Gastrointestinal Hemorrhage/etiology ; Gastrointestinal Hemorrhage/therapy ; Gastrointestinal Hemorrhage/pathology ; Liver Cirrhosis/complications ; Liver Cirrhosis/pathology ; Anticoagulants/therapeutic use ; North America
    • Abstract:
      Introduction: There exists variation regarding the approach to anticoagulation and variceal hemorrhage (VH) prophylaxis among patients with cirrhosis and portal vein thrombosis (PVT).
      Methods: A survey was distributed to gastroenterology and hepatology providers to assess the approach to anticoagulation and VH prophylaxis among patients with PVT in cirrhotic patients.
      Results: Providers were more likely to start anticoagulation if the patient was listed for liver transplantation, was symptomatic, or had superior mesenteric vein thrombosis. For prevention of first VH, many providers opt for combination therapy with both nonselective beta blockers and variceal ligation.
      Discussion: Although providers agree on the clinical scenarios that merit initiation of anticoagulation, practice variation was identified in the means of preventing first VH.
      (Copyright © 2023 by The American College of Gastroenterology.)
    • References:
      Stine JG, Shah PM, Cornella S, et al. Portal vein thrombosis, mortality and hepatic decompensation in patients with cirrhosis: A meta-analysis. World J Hepatol 2015;7(27):2774–80.
      Englesbe MJ, Kubus J, Muhammad W, et al. Portal vein thrombosis and survival in patients with cirrhosis. Liver Transplant 2010;16(1):83–90.
      Ghazaleh S, Beran A, Aburayyan K, et al. Efficacy and safety of anticoagulation in non-malignant portal vein thrombosis in patients with liver cirrhosis: A systematic review and meta-analysis. Ann Gastroenterol 2021;31(1):104–10.
      Mohan B, Aravamudan VM, Khan SR, et al. Treatment response and bleeding events associated with anticoagulant therapy of portal vein thrombosis in cirrhotic patients: Systematic review and meta-analysis. Ann Gastroenterol 2020;33(1):1–17.
      Loffredo L, Pastori D, Farcomeni A, et al. Effects of anticoagulants in patients with cirrhosis and portal vein thrombosis: A systematic review and meta-analysis. Gastroenterology 2017;153(2):480–7.
      Northup P, Garcia-Pagan JC, Garcia-Tsao G, et al. Vascular liver disorders, portal vein thrombosis, and procedural bleeding in patients with liver disease: 2020 practice guidance by the American Association for the Study of Liver Diseases. Hepatology 2021;73(1):366–413.
      EASL clinical practice guidelines: Vascular diseases of the liver. J Hepatol 2016;64(1):179–202.
      Simonetto D, Ashwani S, Garcia-Tsao G, et al. ACG clinical guideline: Disorders of the hepatic and mesenteric circulation. Am J Gastroenterol 2020;115(1):18–40.
      de Franchis R, Bosch J, Garcia-Tsao G, et al. Baveno VII: Renewing consensus in portal hypertension. J Hepatol 2022;76(1):959–74.
      Valla E, Camma C, Marietta M, et al. Enoxaparin prevents portal vein thrombosis and liver decompensation in patients with advanced cirrhosis. Gastroenterology 2012;143(5):1253–60.
      de Franchis R, Bosch J, Garcia-Tsao G, et al. Baveno VII: Renewing consensus in portal hypertension. J Hepatol 2022;76(1):959–74.
      Mohan B, Aravamudan VM, Khan SR, et al. Treatment response and bleeding events associated with anticoagulant therapy of portal vein thrombosis in cirrhotic patients: Systematic review and meta-analysis. Ann Gastroenterol 2020;33(1):1–17.
      Senzolo M, Sartori TM, Rossetto, et al. Prospective evaluation of anticoagulation and transjugular intrahepatic portosystemic shunt for the management of portal vein thrombosis in cirrhosis. Liver Int 2012;32(6):919–27.
      Chung JW, Kim GH, Lee JH, et al. Safety, efficacy, and response predictors of anticoagulation for the treatment of nonmalignant portal-vein thrombosis: A propensity score matching analysis. Clin Mol Hepatol 2014;20(4):384–91.
      Delgado MG, Seijo S, Yepes I, et al. Efficacy and safety of anticoagulation on patients with cirrhosis and portal vein thrombosis. Clin Gastroenterol Hepatol 2012;10(7):776–83.
    • Accession Number:
      0 (Anticoagulants)
    • Publication Date:
      Date Created: 20231226 Date Completed: 20240405 Latest Revision: 20240725
    • Publication Date:
      20240726
    • Accession Number:
      10.14309/ajg.0000000000002640
    • Accession Number:
      38147511